• Store

Medical Marijuana Webinar Archive

Your Patient Takes Medical Marijuana? Evidence Based Research in Action

Obtaining Continuing Nursing Education (CNE)

Viewers are eligible to receive 1 CNE by listening to the program and successfully completing an online posttest and evaluation (free for members, $15 for non-members). Anyone that completes the entire webinar is eligible to receive contact hours.

We urge you to be aware of the continuing education requirements of your own state board of nursing, especially for those states in which continuing education is mandatory.

Purchase Webinar CNE

Download Webinar Handout


With increasing attention to medical cannabis in the media and in professional literature, as well as recent changes to some states’ legislation, nurses are encountering frequent questions regarding the use of medical cannabis in children, adolescents and young adults with cancer and blood disorders. APHON provided two educational sessions about medical cannabis at the 2016 APHON Annual Conference in September. Conference evaluations showed that cannabis content clearly evoked much discussion among attendees. To continue to educate our members and provide different perspectives on this controversial subject, we invite you to join us for our upcoming webinar entitled “Your Patient Takes Medical Marijuana? Evidence Based Research in Action”. This webinar, presented by two APHON members, was well received at the APHON Conference. The webinar presenters will share insights and experience about how one institution addressed issues related to medical cannabis.

Over 6,000 children are registered users of marijuana in Colorado. Many pediatric oncology patients report medical marijuana (MMJ) use. Clinical trials in adults have examined MMJ for cancer-related symptoms. New research is emerging on MMJ in anticancer therapy, MMJ receptors on tumor cells, and the potential role for MMJ as an immunomodulator. Few pediatric oncology studies have evaluated MMJ. We describe a prospective observational study of MMJ on the quality of life (QOL) in pediatric brain tumor patients. Specific aims include (1) MMJ’s association with symptoms (nausea, anxiety, pain, fatigue, cognitive problems, and movement difficulties) and (2) MMJ’s impact on family dynamics, including financial strain. Laboratory assessments of white blood cell function will determine the impact of MMJ on immune function and infection risk. Nurses are the frontline for discussions with patients about MMJ and must be aware of the emerging field of MMJ in pediatric cancer.


Jennifer Madden, CPNP
Pediatric Nurse Practitioner
Children's Hospital Colorado
Aurora, CO

Molly Hemenway, MS RN CPNP
Pediatric Nurse Practitioner
Children's Hospital Colorado
Aurora, CO


  1. Describe the incidence of medical marijuana use in children
  2. Discuss the scientific rationale and current literature for medical marijuana
  3. Describe the current research study for MMJ in Colorado
  4. Discuss the nurse role in MMJ and in the current study
  5. Identify ongoing challenges in the management of pediatric cancers and medical marijuana

Identified Learning Gaps

As a result of attending this activity, the learner will be able to demonstrate an increase knowledge base in:

  • New and innovative therapies in hematology, oncology and hematopoietic progenitor cell transplant
  • Current trends in hematology/oncology and hematopoietic progenitor cell transplant
  • Pharmacotherapy
Learning Outcomes
  1. The learner will be able to identify innovative strategies essential for managing the challenges facing pediatric hematology/oncology nurses and the patients we serve.
  2. The learner will demonstrate increased knowledge related to the care of children, adolescents and young adults with hematologic or oncologic disorders.

The measurement of these outcomes will be evidenced by evaluations and post testing.

Accreditation and Disclaimers

Individual Learning Needs Assessment (ILNA) Coding

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

CPHON® Blueprint

Professional, Treatment or Symptom Management

BMTCN® Blueprint


ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program. Have questions regarding the CPHON® ILNA Coding? Please visit the ONCC website or call them toll-free at 877.769.ONCC (US and Canada only).

Pharmacology Content

This session is eligible for 0.75 pharmacology contact hours.

Accreditation Statement

The Association of Pediatric Hematology/Oncology Nurses (APHON) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Faculty Disclosure of Relevant Financial Relationship(s)

A staff member, volunteer (faculty), or their family member who has an affiliation with a commercial company must declare that relationship in advance of involvement with an education activity that could be used as a forum to promote the interest of that company and its products. The material presented in this activity represents the opinion of the presenters and not necessarily the views of APHON.

Faculty and nurse planners report no conflict of interest with the content of this activity.

Off-Label Use

No off-label use was discussed.